BeOne Newsroom

Media Resources

Corporate Press Kits
Review resources about BeOne.

Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.

Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
May 6, 2026
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
-
April 29, 2026
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
-
April 22, 2026
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
-
February 26, 2026
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
-
February 17, 2026
BeOne Medicines to Present at Upcoming Investor Conferences
-
February 11, 2026
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
-
January 13, 2026
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
-
January 6, 2026
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
-
January 6, 2026
BeOne Medicines’ Novel BCL2 Inhibitor, Sonrotoclax, Achieves First-in-World Approval in R/R MCL and R/R CLL/SLL
-
December 23, 2025
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
December 18, 2025
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
-
December 8, 2025
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Congress Hub
Review the latest information about the data we’re presenting and where you can find us.

Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More

Our Pipeline
Our cancer pipeline is one of the most promising and prolific in the industry.